29 NovA further list and description of risks and uncertainties.

A further list and description of risks and uncertainties, in Pfizer’s Annual Report on Form 10 – K for the year ended 31 December 2004, and found in its reports on Form 10-Q and Form 8-K.

Timothy Hill, Chief Financial Director and Head of the Office of Financial Management at CMS testified at the hearing that the agency has a plan to meet the requirements developed. CMS officials also said program we have no authority to recover overpayments to MA plans Xavier Becerra. Xavier Becerra (D-Calif. That CMS officials such such authority.Pnina Fishman, company CEO: We are very pleased with these preliminary data and are to the fact that that trial achieved all its goals was delighted demonstrated not only CF102 that sure at all doses, having well. Pharmacokinetic profile pharmacokinetic profile, by the fact that the patients reached such an impressive median survival time spite their advanced underlying illness encourages us to next the development of for patients with liver disorders. .. The preliminary analysis of data the study provides successfully met its objectives, According to Dr. Favorable safety profile of CF102 in a patient population primary liver cancer and Child-Pugh cirrhosis classes A and B.